"Patients with a type of cancer known as primary mediastinal B-cell lymphoma who received infusions of chemotherapy, but who did not have radiation therapy to an area of the thorax known as the mediastinum, had excellent outcomes, according to "...
Pamidronate Disodium Injection
(pamidronate disodium) Injection, Solution
(pamidronate disodium) Injection, Powder, Lyophilized, for Isolution
For Intravenous Infusion
Pamidronate Disodium Injection is a bone resorption inhibitor available in 30 mg vials for intravenous administration. Each mL contains 3 mg of pamidronate disodium; 47 mg of mannitol USP and water for injection q.s.; phosphoric acid and/or sodium hydroxide have been added to adjust pH 6.2 to 7.0.
Pamidronate Disodium for Injection is a bone resorption inhibitor available in 30 mg and 90 mg vials for intravenous administration. Each 30 mg and 90 mg vial contains, respectively, 30 mg and 90 mg of sterile, lyophilized pamidronate disodium and 470 mg and 375 mg of mannitol USP.
Inactive Ingredients: Mannitol and phosphoric acid (for adjustment to pH 6.5 prior to lyophilization).
The pH of a 1% solution of pamidronate disodium in distilled water is approximately 8.3. Pamidronate disodium, a member of the group of chemical compounds known as bisphosphonates, is an analog of pyrophosphate. Pamidronate disodium is designated chemically as disodium dihydrogen (3-amino-1-hydroxypropylidene) diphosphonate, and its structural formula is:
Pamidronate disodium is a white-to-practically-white powder. It is soluble in water and in 2N sodium hydroxide, sparingly soluble in 0.1N hydrochloric acid and in 0.1N acetic acid, and practically insoluble in organic solvents. Its molecular formula is C3H9NO7P2Na2 and its molecular weight is 279.1.
Last reviewed on RxList: 2/10/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Pamidronate Disodium Injection Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.